-
Mashup Score: 4Rheumatology - 7 month(s) ago
The official journal of the British Society for Rheumatology. Publishes high-quality scientific (basic and translational) and clinical-epidemiological papers on a wide range of paediatric and adult rheumatological and musculoskeletal conditions.
Source: academic.oup.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort - 9 month(s) ago
Alessandro Tomelleri, Giovanni Benanti, Adriana Cariddi, Stefania Laura Calvisi, Elena Baldissera, Nicola Boffini, Marco Matucci-Cerinic, Lorenzo Dagna; The imp
Source: academic.oup.comCategories: Latest Headlines, RheumatologyTweet-
New on #AdvanceAccess: The impact of #EMA recommendations on patients treated with #JAKi: real-life experience from @tomelleri_a et al. Check it out 👇 https://t.co/1OYy4EMfJ1 @lorenzodagna
-
-
Mashup Score: 3
Background JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since JAKi approval, in an international collaboration of 19 registers. Methods In this observational cohort study, patients initiating tumour necrosis…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#JAKi #TNFi #abatacept anti- #IL6 New results of the #Jakpot collaboration: 30000 treatment courses - 19 registries Real life effectiveness and safety outcomes ❗️Discontinuation rates similar between differently targeting drugs https://t.co/HJL5f0dS4Q https://t.co/Q0VDG6AAS2
-
-
Mashup Score: 0After 25 years of drug development, do we know JAK? - 2 year(s) ago
The discovery of Janus kinase (JAK) proteins in the early 1990s,1 which led to the approval of tofacitinib in rheumatoid arthritis (RA) decades later, serves as an illustrative case study of drug development (figure 1). The potential for therapeutic targeting of the JAK family first became apparent when it was found that patients with inactivating mutations in JAK3 developed severe combined…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet-
What do we know about #JAKi after 25 years of drug development? ▶️ efficacy and safety profile ▶️ lessons and new questions from #ORAL Surveillance study ▶️ real complexity of JAK signalling in patients 🔗 https://t.co/zf38FSeCUp
-
-
Mashup Score: 3Waiting for JAK inhibitor safety data - 2 year(s) ago
The US Food and Drug Administration (FDA) has recently added a new ‘black box warning’ on all currently approved Janus kinase (JAK) inhibitors indicated for the treatment of arthritis and other inflammatory conditions based on results from the ORAL Surveillance study of tofacitinib versus tumour necrosis factor alpha inhibitors in rheumatoid arthritis. This is a warning difficult to ignore…
Source: RMD OpenCategories: Latest Headlines, RheumatologyTweet-
Have you listened our latest #podcast @bmj on JAKi after the ORAL surveillance study? RMD Open Article ➡️https://t.co/3S60PMHhHK Podcast ➡️https://t.co/T1RQAF5u5P @DrCMcMaster @philipcrobinson @drdavidliew @KragstrupTW @javierrcarrio #SoundCloud #rheumatology #JAKi
-
-
Mashup Score: 0
Background JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since JAKi approval, in an international collaboration of 19 registers. Methods In this observational cohort study, patients initiating tumour necrosis…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
#JAK-pot; #RA Drug discontinuation and 1 year response rates of #JAKi and #IL-6i were similar to those observed with TNFi. Compared with #TNFi, JAKi were more often discontinued for adverse events and less for ineffectiveness, as were IL-6i https://t.co/Md0SrMmbzN https://t.co/hk8yuCvKdO
-
-
Mashup Score: 0Mixed results for MACE risk with JAK inhibitors in RA - 2 year(s) ago
Two real-world studies looking at the risk for major cardiovascular events with JAK inhibitors versus TNF inhibitors in patients with rheumatoid arthritis show contradicting outcomes.
Source: rheumatology.medicinematters.comCategories: Latest Headlines, RheumatologyTweet-
#EULAR2022 news: Two real-world studies looking at MACE and VTE risk with JAK inhibitors vs TNF inhibitors in #RheumatoidArthritis show conflicting results. Click through for the details @CHUdeToulouse @DRFZ_Berlin #JAKi #TNFi https://t.co/MzBDgZyiWN
-
-
Mashup Score: 4Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial - 2 year(s) ago
The results of this pivotal trial show that tofacitinib is an effective treatment in patients with polyarticular course JIA. New oral therapies are particularly relevant for children and adolescents, who might prefer to avoid injections.
Source: The LancetCategories: Latest Headlines, RheumatologyTweet-
#ResearchHighlight | Tofacitinib a promising oral therapy for JIA #rheumatology #JIA #JAKI Read the original research from @TheLancet here https://t.co/VMJoZO8YGv Read our #news story here https://t.co/WLzvh8cVjn
-
-
Mashup Score: 5Texas Myeloproliferative Neoplasms (MPN) Virtual Workshop | UT Health San Antonio MD Anderson Cancer Center - 3 year(s) ago
About About This Event Mays Cancer Center, home to UT Health San Antonio MD Anderson, invites you to attend the Second Annual 2021 Texas Myeloproliferative Neoplasms (MPN) Virtual Workshop. The focus of this workshop is to bring together medical experts in the field of MPNs to discuss the many new research and therapy options in…
Source: cancer.uthscsa.eduCategories: Hem/Oncs, Latest HeadlinesTweet-
Join us for the 2nd Annual Virtual #TexasMPNWorkshop21 #TMW21. *Free* registration, all are welcome: https://t.co/KfLgHFiIi8 World-renowned line-up of speakers @mpdrc @doctorpemm Verstovsek Discussions about #inflammation, #JAKi, novel therapies, #COVID19 in MPN #MPNSM https://t.co/mHp4qOx5R2
-
-
Mashup Score: 0JAK Inhibitors Appear Hopeful for Transplant-Eligible MPN Patients in Retrospective Data - 4 year(s) ago
Uday R. Popat, MD, discusses the role of JAK inhibitors in patients with myeloproliferative neoplasms.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Popat discusses the role of JAK inhibitors in patients with myeloproliferative neoplasms. https://t.co/SX8qAnR973 #mpnsm #JAKi
-
Rheumatology's October issue is now online! Featuring: ⭐ @drdj's choice: Two articles looking at risks with #JAKi 🤖 #AI for #rheumatology 💸 Cost-effectiveness #research 📈 Results from the @BSRBR_RA 📚 Health literacy 🩸 #Proteomics & more https://t.co/Q4zDVUaPX6